MEDINCELL Stock: Significant Decline Over the Week in a Falling Paris Market
Medincell stock experienced a clear correction phase over the week, aligning with a generally downward-oriented stock market context. Its annual performance, however, remains strongly positive. At the same time, major Parisian indices also faced notable declines.
Over the past week, Medincell stock closed at 28.26 euros, down by 7.95%. This decrease contrasts with the bullish momentum that has driven the stock over the year, where it has seen a rise of 64.3%. The week was marked by a series of negative sessions, with the stock dropping from 30.32 euros at the week's start to 28.26 euros at the close. Trading volumes increased towards the end of the week, indicating a heightened activity around the stock with nearly 176,000 shares traded in the last session. This correction occurred as the CAC 40 and SBF 120 also recorded declines of 3.04% and 2.98% respectively, reflecting a widespread retreat in the Paris market.
Technical Analysis and Support Levels
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Technically, the stock is now immediately at its main support threshold, precisely at 28.26 euros. Compared to the 50-day moving average positioned at 29.50 euros, the stock currently shows a negative deviation, indicating a short-term break. The 200-day moving average, much further at 19.11 euros, however, reflects the underlying bullish trend over the past months. The volatility indicator stands at 17.00 over a month, while the RSI, at 17, indicates that the stock has been in an oversold zone since mid-week. Bollinger Bands, spanning from 26.04 euros to 39.65 euros, highlight the current extent of price fluctuations, while the MACD remains in negative territory. Overall, these elements illustrate strong selling pressure on Medincell in the very short term, in a stock market environment characterized by nervousness and increased volatility.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
